1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
2. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
a. Dostarlimab
b. Hormone therapy (Progesterone or Letrozole)
c. Pembrolizumab monotherapy
d. Pembrolizumab in combination with Lenvatinib
e. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
f. Any other SACT
3. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
a. Hormone therapy (Progesterone or Letrozole)
b. Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
c. Any other SACT
4. Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
